HDL cholesterol and cardiovascular risk Epidemiological evidence

Slides:



Advertisements
Similar presentations
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Advertisements

Lipid Disorders and Management in Diabetes
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
Diabetes Trials Unit University of Oxford WebSite: Lipids in Diabetes Study.
 High density lipoproteins (HDL) protect against cardiovascular disease  A novel mechanism for raising HDL levels is to inhibit a protein known as CETP.
Global impact of ischemic heart disease World Heart Federation, 2011.
HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.
Epidemiology of CVD in the Elderly Karen P. Alexander MD Duke University Medical Center Duke Clinical Research Institute Disclosures: (1) Minor Research:
Modern Management of Cholesterol in the High-Risk Patient.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
Slide Source: Lipids Online Slide Library Collaborative Atorvastatin Diabetes Study (CARDS) Type 2 diabetes mellitus Men and women.
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.
Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
Date of download: 6/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Major Lipids, Apolipoproteins, and Risk of Vascular.
○ South Asians (SAs) have high rates of CHD which are not entirely explained by traditional CVD risk factors. ○ The association of a family history of.
Blood Pressure and Lipid Trials: Rationale, Importance and Design
NICE –CG 181 Continuum of CVD Risk and its treatment
Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial Michael Miller MD,
US cost-effectiveness of simvastatin in 20,536 people at different levels of vascular disease risk: randomised placebo-controlled trial UK Medical Research.
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Ungroup once.
Title slide.
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals
Should we move from Lipids to Lipoproteins, from Dyslipidemia to Dyslipoproteinemia in future guidelines for CVD?
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
Cholesterol Lowering and CV Risk: Meta-analyses
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.
Pravastatin in Elderly Individuals at Risk of Vascular Disease
Triglycerides Cholesterol HDL-C or N NIDDM N or or N IDDM.
The Anglo Scandinavian Cardiac Outcomes Trial
ELIGIBILITY: MRC/BHF Heart Protection Study
PS Sever, PM Rothwell, SC Howard, JE Dobson, B Dahlöf,
AIM HIGH Niacin plus Statin to prevent vascular events
First time a CETP inhibitor shows reduction of serious CV events
Copyright © 2012 American Medical Association. All rights reserved.
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
HDL cholesterol and cardiovascular risk
AIM-HIGH Niacin Plus Statin to Prevent Vascular Events
Oxford Niacin Trial.
FATS- Familial Atherosclerosis Treatment Study
TNT: Baseline and final LDL cholesterol levels
Progress and Promise in RAAS Blockade
Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group
These slides highlight a cardiology grand rounds and cardiology research rounds presented by William James Howard, MD at St. Michael’s Hospital, in Toronto,
Baseline characteristics of HPS participants by prior diabetes
The Hypertension in the Very Elderly Trial (HYVET)
The results of the SHARP trial
Type 2 diabetes: Overlap of clinical conditions
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
Description of studies for pooled analyses
Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies 
Lipid-Lowering Arm (ASCOT-LLA): Results in the Subgroup of Patients with Diabetes Peter S. Sever, Bjorn Dahlöf, Neil Poulter, Hans Wedel, for the.
These slides highlight a presentation from a Special Session of the Late-Breaking Clinical Trials sessions during the American College of Cardiology 2005.
LRC-CPPT and MRFIT Content Points:
Potential mechanisms whereby statins may reduce the risk of stroke
The following slides are from a Cardiology Scientific Update in which Dr. Gordon Moe reported and discussed an original presentation by Drs. Bjorn Dahlof,
Goals & Guidelines A summary of international guidelines for CHD
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
Baseline Characteristics of the Subjects*
The results of the SHARP trial
PROSPER: trial design                                                                                                                                                                 
The following slides highlight a report on a presentation at the American College of Cardiology 2004, Scientific Sessions, in New Orleans, Louisiana on.
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm
Presentation transcript:

HDL cholesterol and cardiovascular risk Epidemiological evidence

FRAMINGHAM: LDL, HDL AND CHD RISK Independent risk associated with low HDL-C The Framingham heart study demonstrated that there was a statistically significant increase in the number of coronary heart disease (CHD) events in individuals with low high-density lipoprotein cholesterol (HDL-C, <34 mg/dL). This was especially evident in women (p<.01).1,2 As HDL-C decreases, it contributes significantly to CHD risk at all levels of low-density lipoprotein cholesterol (LDL-C).3 References 1. Kannel WB. High-density lipoproteins: epidemiologic profile and risks of coronary artery disease Am J Cardiol. 1983;52:9B-12B. 2. Wilson PWF, et al. Prediction of coronary heart disease using risk factor categories Circulation. 1998;97:1837-1847. 3. Gordon T et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-714. Men aged 50-70 years Gordon T et al. Am J Med 1977;62:707-714.

Meta-analysis: Predictive Value of HDL cholesterol CPPT: Coronary Primary Prevention Trial LRCF: Lipid Research Clinics Prevalence Mortality Follow-up Study MRFIT: Multiple Risk Factor Intervention Trial FHS: Framingham Heart Study. Meta-analysis of four large prospective studies (the Framingham Study, Lipid Research Clinics Prevalence Mortality Follow-up Study, Coronary Primary Prevention Trial and Multiple Risk Factor Intervention Trial) consistently showed that for every 1 mg/dL (0.026 mmol/L) decrease in plasma levels of HDL-C there was a 2-3% increase in the risk of CHD, independent of other risk factors, including plasma LDL‑C.1 Reference 1. Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15. 2%  in risk for men 1 mg/dL  in HDL-C 3%  in risk for women

InterHEART: Global Study Association of AMI with Risk Factors % Cont % Cases OR adj for age, sex, smoking OR adj for all ApoB/ApoA-1 20.0 33.5 3.87 3.25 Smoking 26.8 45.2 2.95 2.87 Diabetes 7.5 18.4 3.08 2.37 Hypertension 21.9 39.0 2.48 1.91 Abdominal obesity 33.3 46.3 2.22 1.62 Psychosocial - 2.51 2.67 Veg & fruits daily 42.4 35.8 0.70 Exercise 19.3 14.3 0.72 0.86 Alcohol Intake 24.5 24.0 0.79 0.91 All combined 129 All combined (extremes) 334 333 Findings from INTERHEART, a global case control study of heart attack involving 52 countries, imply that even in patients with low levels of LDL cholesterol, if the level of HDL cholesterol is not sufficiently high, there remains an increased risk of further cardiovascular events. This scenario can be explained on the basis of an imbalance between the deposition and removal of cholesterol in the arterial wall. Maintaining high levels of HDL cholesterol in the plasma ensures that the HDL can counter the effects of atherogenic lipoproteins and prevent or even reduce progression of atherosclerosis. Reference Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-52. Yusuf S et al ; Lancet 2004; 364: 937

Total cases (n=18,368) Non-fatal MI (n=8,857) CHD Death (n=3,928) Emerging Risk Factors Collaboration: First-ever outcomes, 2.79 million person-years Total cases (n=18,368) Non-fatal MI (n=8,857) CHD Death (n=3,928) Stroke* (n=5,583) The Emerging Risk Factors Collaboration provides the largest body of evidence supportive of HDL cholesterol as a cardiovascular risk factor. This analysis included data from 302,430 subjects without known history of coronary heart disease (CHD) from 68 prospective population-based studies. Over 2.79 million person-years of follow-up, there were 18,368 first-ever outcomes (12,785 CHD events). Reference The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000 *2,534 ischemic stroke, 513 hemorrhagic stroke and 2,536 unclassified stroke. ERFC. JAMA 2009;302:1993-2000

Emerging Risk Factors Collaboration: Adjusted Emerging Risk Factors Collaboration: Adjusted* hazard ratios for CHD risk Lipid Hazard ratio (95% CI) HDL-C 0.78 (0.74-0.82) Non-HDL-C 1.50 (1.39-1.61) TG 0.99 (0.94-1.05) Hazard ratios were calculated per 1 standard deviation higher values of triglycerides (1 SD = 0.52 loge), HDL cholesterol (15 mg/dL), non-HDL cholesterol (43 mg/dL), apolipoproteins (apo) AI or B (29 mg/dL each) and directly measured LDL cholesterol (33 mg/dL). Adjustment was made for age, sex, systolic blood pressure, smoking status, diabetes history, body mass index and lipid measures. HDL cholesterol and non-HDL cholesterol levels were strongly associated with CHD risk, albeit in opposite directions, with risk increasing in a log-linear manner, independently of each other. An increase in HDL cholesterol by 15 mg/dL was associated with 22% reduction in CHD risk. Triglyceride levels did not impact on CHD risk (hazard ratio 0.99, 95% CI 0.94-1.05) after adjustment. Similar associations were shown for ischaemic stroke. Reference The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000 * Adjusted for age, sex, systolic BP, smoking, history of diabetes, BMI and lipids ERFC. JAMA 2009;302:1993-2000

Emerging Risk Factors Collaboration: Adjusted Emerging Risk Factors Collaboration: Adjusted* hazard ratios for CHD risk HDL-C Hazard ratio (95% CI) fasting 0.79 (0.74-0.84) non-fasting 0.75 (0.68-0.83) Adjusted for non-lipid factors 0.71 (0.68-0.75) Adjusted for Non-HDL-C, TG 0.78 (0.74-0.82) Hazard ratios were at least as strong in individuals who fasted compared with those who did not. Adjustment for lipid or non-lipid risk factors did not appear to influence hazard ratios for CHD risk. Reference The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000 * Adjusted for age, sex, SBP, smoking, history of diabetes, BMI and lipid measures. ERFC. JAMA 2009;302:1993-2000

Low HDL-C increases cardiovascular risk in high-risk statin-treated patients Meta-analysis of 14 statin studies showed that patients with a low level of HDL cholesterol (35 mg/dL or 0.9 mmol/L) had a higher risk of further cardiovascular events than control patients with high HDL cholesterol levels (42.5 mg/dL or 1.1 mmol/L). Statin treatment did not affect this excess risk.1 The CTT have recently reported an updated meta-analysis to evaluate the effect of intensive LDL cholesterol lowering on this association. Data from 170,000 individuals involved in 26 randomised trials, five which compared more versus less intensive statin treatment (n=39 612 patients), were included. In a planned subgroup analysis, the CTT showed that the risk reduction for upper versus lower HDL tertiles (>1.3 mmol/L versus 1.0 mmol/L) was similar in individuals treated with more or less intensive statin therapy. Cardiovascular risk was always lower at higher levels of achieved HDL cholesterol concentration irrespective of the level of achieved LDL-C or the intensity of statin therapy. There was no evidence of attenuation of this relationship at low LDL-C levels.2 References 1. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78. 2. Cholesterol Treatment Trialists' Ctt Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010;376:1670-81. Baigent et al. Lancet 2005;366;1267-78

High HDL-C decreases cardiovascular risk at low LDL-C (<70 mg/dL) – TNT study 39% lower risk The TNT study was designed to investigate the effect on cardiovascular risk of lowering LDL cholesterol levels to <70 mg/dL (<1.8 mmol/L). The study included 10,001 patients with stable CHD, who were randomized to either atorvastatin 80 mg/day or 10 mg/day. Patients were followed-up for a median of 4.9 years. The primary study endpoint was major cardiovascular events, defined as CHD death, non-fatal, non-procedural myocardial infarction, resuscitation after cardiac arrest or fatal or nonfatal stroke. Subgroup analyses showed that even at low levels of LDL cholesterol (<70 mg/dL), patients with HDL cholesterol levels >55 mg/dL (>1.42 mmol/L) had a 39% lower risk of major cardiovascular events than those with levels <37 mg/dL (<0.96 mmol/L) (Hazard ratio 0.61, 95%CI 0.38 to 0.97). Reference Barter PJ, Gotto AM, LaRosa JC et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-1310. Barter P et al. N Engl J Med 2007;357:1301-1310

Major cardiovascular event frequency by LDL and HDL levels - TNT study The predictive power of a low HDL cholesterol plasma level in people with very low levels of LDL cholesterol remained significant even after adjusting for age and gender, smoking, hypertension, body mass index, fasting glucose, presence of diabetes, prior cardiovascular disease, on-treatment triglyceride concentration and baseline level of LDL cholesterol (p=0.03). Reference Barter PJ, Gotto AM, LaRosa JC et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357:1301-1310. * Men 50 to 70 years of age, unadjusted data. Barter P et al. N Engl J Med 2007;357:1301-1310